Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review-Reference-Cited by-同舟云学术

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Published:2019-03-18 Issue:3 Volume:19 Page:243-244
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Deitelzweig Steve¹²,Lip Gregory Y. H.³⁴

Affiliation:

1. Department of Hospital Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA

2. School of Medicine, Ochsner Clinical School, The University of Queensland, New Orleans, LA, USA

3. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK

4. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Funder

Pfizer Inc

Bristol-Myers Squibb Company

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1592834

Reference6 articles.

1. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation

2. COMPARE MAJOR BLEEDING RISK AND ASSOCIATED COSTS AMONG NVAF PATIENTS WITH CHA2DS2-VASC SCORE ≥ 3 NEWLY ANTICOAGULATED WITH APIXABAN VERSUS WARFARIN

3. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Minimally Invasive Thoracoscopic Left Atrial Appendage Excision on Cardiac Dynamic and Endocrine Function;Annals of Thoracic and Cardiovascular Surgery;2021

2. Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study;Journal of Comparative Effectiveness Research;2019-10